Abstract. Among various laboratory and clinical features megakaryocytopoiesis and platelet (PLT) counts have been previously insufficiently evaluated for their prognostic significance in acute myelogenous leukaemia (AML). We studied several clinical and laboratory features of 108 first diagnosed AML patients in relation with their prognosis. Patients with favourable prognostic features were excluded from the study. This study focused on the prognostic impact of PLT counts and related molecular biology in AML patients at initial diagnosis. In particular, the PLT counts were correlated with the endogenous production of thrombopoietin (TPO), c-mpl expression, CD34 + leukemic blast cell proportion, cytogenetics, and a prognostic correlation was established. We found that the most favorable prognosis appeared in the AML patient group with PLTs <25x10 9 /l and correlated to cytogenetic findings (normal or abnormal karyotypes), while by far the most unfavorable prognosis was found in the patient group with PLTs ≥130x10 9 /l independent of the corresponding cytogenetics. It was demonstrated that AML patients with normal or elevated PLT counts at first presentation, may constitute a distinct patient group with particular characteristics such as higher levels of endogenous TPO production, high expression of CD34 + leukemic blast cells, higher expression of c-mpl and consequently low response to chemotherapy and a very poor prognosis. These correlations between PLTs production (megakaryothrombopoiesis), TPO serum levels and TPO receptor (c-mpl) expression may help in the determination of risk-adapted AML patient groups and of targeted therapeutic strategies.
Introduction
In acute myelogenous leukemia (AML) all myeloid lineages and differentiation pathways are affected directly or indirectly up to a certain degree. Megakaryocytopoiesis represents one of these differentiation pathways that haemopoietic stem cells may enter. In AML, megakaryocytopoiesis and thrombopoiesis defects vary, presenting as hypoplastic or absent megakaryocytopoiesis [which results in reduced numbers of platelets (PLT) or even severe thrombocytopenia, PLT: <25,000/μl], or as normal or dysplastic or hyperplastic thrombothrophic features (which result in normal or elevated, in the case of thrombocytosis, PLT numbers). Leukemia blast clonal chromosome rearrangements of 3q21 or 3q26 have been correlated with the AML cases presenting normal or elevated PLT counts (1) . Although low PLT counts at the time of AML diagnosis can be interpreted as the result of suppression of normal hematopoiesis by a leukemia clone that lacks megakaryocytic differentiation, AML still represents a clonal stem cell disorder. Thus, the effectiveness of thrombopoiesis may be an important factor in disease pathophysiology and evolution (2, 3) .
Although several clinical and laboratory parameters, including platelet counts and megakaryocytopoiesis, have been previously studied in order to designate prognosis in AML, the prognostic value of PLT production has not been clearly determined (3, (4) (5) (6) (7) .
Thrombopoietin (TPO) is a growth factor for megakaryocyte progenitor cells and can also modulate platelet function. Among the growth factor receptors that have been shown to be expressed by human AML blasts is the cloned receptor for thrombopoietin, c-mpl, which reveals considerable sequence similarity to other receptors of the class I hematopoietin receptor superfamily. Within the physiological ONCOLOGY REPORTS 19: 1021 -1026 , 2008 Platelet production and related pathophysiology in acute myelogenous leukemia at first diagnosis: Prognostic implications hematopoiesis, c-mpl is expressed on megakaryocytes, platelets, and on a large fraction of CD34 cells from which TPO enhances megakaryocyte formation and maturation (8, 9) . TPO levels and c-mpl expression seem to be involved in the growth of myeloid leukemia and may be related with the immaturity of the transformed progenitor cells and consequently with the prognosis of AML (10) . We studied the prognostic implications of several clinical and laboratory features of 108 first diagnosed AML patients. Patients with favourable prognostic features were excluded. The objectives of this study focused on the prognostic impact of PLT counts and related molecular biology. The PLT counts in the studied patients were correlated with the endogenous production of thrombopoietin (TPO), c-mpl expression, CD34 + leukemic blast cell proportion, cytogenetics, and a prognostic correlation was established.
Materials and methods
Patient inclusion and classification. We studied first diagnosed adult AML patients (pts). Patients with good prognostic features such as with karyotypic abnormalities like paracentric inversion of chromosome 16 or translocations 8;21 and 15;17, promyelocytic leukemia (M3), and those treated with allogenic bone marrow transplantation (ABMT) were excluded from our study (~16% in total) (11) . In total, 108 pts were included in our study. Laboratory and clinical data at AML initial presentation are described in Table I . As discussed below, several of these parameters were considered of prognostic value and in certain cases they were well established, as it was previously reported (4-7). The pts were classified in three groups according to their PLT counts at diagnosis. These groups were divided into subgroups according to the cytogenetic findings (Table II) . In the first subgroup, we classified the pts that revealed abnormal karyotypes (AK), while in the second subgroup the pts with normal karyotypes (NK). The AML cases were diagnosed according to morphological, cytochemical and immunophenotypical criteria, and are presented according to the French-American-British (FAB) classification (12, 13) . Metaphases were G-banded and karyotypes were analysed according to ISSN (14) . Megakaryocytopoiesis in bone marrow aspirations was studied and classified in three types according to Jinnai et al (2) . In the first patient group there were no detectable mega-caryocytes (type I), in the second patient group normal (type II) or slightly dysplastic megakaryocytes were detected, and in the third patient group slightly or marked dysplastic megacaryocytic changes (type III) were revealed. Platelet count which expresses the megakaryopoietic status in leukaemia as well as karyotype (abnormal or normal) were evaluated either as correlated or as independent prognostic parameters. Complete response in percentage (%CR), mean duration of CR and 2-year diseasefree survivors (2y-DFS) in patient groups and subgroups are also demonstrated (Table II) TPO assessment. Concentrations of TPO in sera were determined using specific ELISA analysis (Quantikine ELISA assays; R&D Systems Europe, UK) as previously described (15) . Analysis was performed strictly according to the manufacturer's instructions with standards and sample dilutions prepared in the supplied diluents. Standard curves were determined using the mean of duplicate analyses. TPO minimal detectable levels in serum samples were 20 pg/ml.
Determination of CD34 expression. The determination of CD34 expression on mononuclear cells that were collected with Ficoll-separation from the peripheral blood of the studied pts was performed with flow cytometry methods. Cell suspensions (50 μl) were incubated with 10 ml phycoerythrinconjugated HPCA-2 (anti-CD34 PE; Becton Dickinson, San Jose, CA) for 20 min at 4˚C. After washing, 10,000 events were counted using a Coulter flow cytometer. The blast populations were gated using scatter parameters. An irrelevant, isotype-matched MoAb was used as negative control. Data were analyzed and CD34 expression >10% of the blast population was interpreted as significant expression (16).
c-mpl protein determination. The c-mpl protein was quantified by the solid-phase RIA method as previously described (17, 18) . RIA plates were coated overnight at 4˚C with 5 mg of protein extracted from peripheral blood mononuclear cells of patients and normal individuals (control) in 50 ml PBS. After washing with PBS and blocking with 100 ml 1% BSA for 1 h at 37˚C, the plates were incubated overnight at 4˚C with 50 ml mouse anti-c-mpl antibody (Genezyme, Cambridge, MA) diluted 1:500 in PBS containing 1% BSA. Then, plates were washed with PBS and amplified with rabbit anti-mouse-IgG antisera and after washing, were developed with excess iodine-125-labeled protein A [200,000 cpm (50 IU)] for 2 h at room temperature, and the contents of each well were counted with a gamma counter. The assays were performed in triplicate. The median c-mpl expression detected in the normal samples was assigned a score of 1.0, and levels in AML were expressed in proportion to this value. 
Results
The clinical and laboratory features performed at initial presentation in the AML patients that were included in our study are presented in Table I . - Table II . Percentage of complete remission (CR), mean duration of CR and 2-year DFS in patient groups and subgroups, classified according to platelet (PLT) counts and to karyotype (normal, NK or abnormal, AK), are presented. Pts in total with NK (n=42, 39%) 67 9.9
5/42 -----------------------------------------------------------------------------------------------------
a The values of each group and subgroup were compared with the respective values for the rest of the pts and significance levels (p<0.05) are shown.
-----------------------------------------------------------------------------------------------------
The most frequent karyotypic findings were trisomy of chromosome 8 and paracentric invertion of chromosome 3 found in 10 and 6 pts, respectively. Sixty-five pts (65/108, 60%) presented chromosomal aberrations. Twelve pts of the third study group (50%) showed the following karyotypic anomalies: inv(3)(q21q26) (in 6 pts), del(7)(p12p21) (in 3 pts), t(3;3)(q21;q26) (in 2 pts), and del(1l)(q22) (in one patient). Thrombocytosis (PLTs >500x10 9 /l) appeared in the first six pts with inv(3).
Prognostic parameters in the groups of the AML patients are shown in Table II . Our results indicate that the percentage of complete remission (CR) was independent of normal (NK) or abnormal karyotype (AK) in the three patient groups. Nevertheless, a trend to lower remission rates from pts with PLTs <25x10 9 /l (Group 1) and NK (80% CR) to pts with PLTs >130x10 9 /l (50% CR) (Group 3) was evident. Also, the mean duration of CR was independent of NK or AK in the total number of pts. However, in Group 2 the mean duration of CR in pts with AK was significantly lower (p<0.001). Moreover, it appeared to be significantly longer in Group 1 and significantly shorter in Group 3, while it was independent of the presence of AK in these two groups. Group 2 represents the majority of the pts (48%), and an intermediate mean CR duration was found. The 2-year disease-free survival (2y-DFS) was nilpotent among the 24 pts of Group 3. The presence of AK showed prognostic significance only in Group 2. Prognosis in Group 3 was severe, showing the lowest CR rates and CR duration, as well as null 2y-DFS. No correlation between PLT counts and AML subtypes in the studied patients was deduced.
The mean values of endogenous TPO levels and of the expression of its receptor (c-mpl) were significantly higher than normal subjects in all groups of patients, while the highest values were demonstrated in Group 3 patients (Table III) . Moreover, a significant expression of CD34 + leukemic blast population was found in 100% of patients in Group 3 (Table III) .
In summary, AML patients at first diagnosis exhibit PLT counts >130x10 9 /l, chromosome 3 abnormalities, poor prognosis, higher production of TPO, and higher expression of c-mpl with high frequency. Furthermore, a significant expression of CD34
+ blast cells appears in all the cases.
Discussion
Although that platelet counts under 20,000 25x10 9 /l in AML patients are associated with a substantial risk of lifethreatening hemorrhage (19) , our study indicated that the best prognosis was observed in Group 1 (PLTs <25x10 9 /l). On the other hand, the worst prognosis was found in Group 3 (PLTs >130x10 9 /l). Group 3 pts presented the most favorable prognostic features of lower white blood cell (WBC) counts, lower percentage of peripheral blood blast cells, lower incidence of high temperature, lower LDH, higher hematocrit, no incidence of abnormal liver function, no demostration of splenomegaly, no demostration of hemorrhagic symptoms and lower incidence of infections (Table I) (4-7) . Thus, the status of thrombopoiesis and the PLT production in AML seem to play an important prognostic role. The low PLT counts in AML may reflect the depression of megakaryopoiesis by the leukemic blast cell propagation, while in the case of AML with normal or elevated PLT count the megakaryopoiesis is also primarily involved with the leukemic transformation signifying hyperplastic properties. In the latter case, the malignant impairment is found in more immature stages of hemopoiesis affecting the megakaryopoietic cell lineage. This view can be supported by the observation that a significant expression of CD34 on leukemic blast population was found in 100% of patients in Group 3. A hypothesis that could interpret unfavorable prognosis in AML patients with normal or elevated PLT counts at initial diagnosis is the case of a group of secondary leukemia patients having evolved from a fast-progressed myelodysplastic syndrome (MDS).
Thrombopoietin (TPO), the ligand for c-mpl, is a glycoprotein promoting the proliferation of megakaryocytic precursors, and subsequently their differentiation into megakaryocytic and platelet cell lines (20, 21) . Zwierzina et al showed that endogenous TPO production is upregulated by a decreased circulating platelet count only in patients with refractory anemia (22) . In the more advanced stages of MDS Table III . Mean levels of endogenous TPO (pg/ml) and relative median c-mpl expression in blood samples of the studied patients; percent of patients that showed CD34 + on leukemic blast cells; significance levels (P) in comparison to control values, are demonstrated.
Mean TPO levels Relative median CD34 + (%) (range) (pg/ml) P c-mpl expression a P - -------------------------------------------------------------------------------------------------- 
a Levels are in proportion to median c-mpl levels in normal controls. Normal control median is 1.0.
-
where the leukemic clone has further progressed, an inadequate TPO response occurs, possibly due to overexpression of the mpl receptor by the malignant clone. An elevation in the endogenous levels of TPO, IL-6 and IL-8 in the thrombocytopenic patients with AML and MDS was observed by Hsu et al (23) . We also recorded a significant elevation of endogenous TPO (Table III) in thrombocytopenic AML patients (Groups 1 and 2) . Unexpectedly, the patients with normal or elevated PLT counts (Group 3) presented the highest TPO levels. In AML patients endogenous TPO may increase proportionally with PLT production and this increase is not the compensative effect of thrombocytopenia alone. Moreover, in AML patients with normal or elevated PLT counts, stem cell disorders involving TPO overproduction or c-mpl dysfunctional mutations may occur. Furthermore, as TPO overexpression is detected in several AML cases, it promotes the proliferation of leukemic blasts (24) . The possibility of an increased sensitivity of megakaryoblasts to TPO has not been investigated in detail.
Despite the fact that the main clinical importance of chromosome aberrations in hematological disorders is diagnostic, in several AML cases it appears to be of prognostic value. Abnormalities of 3q chromosome are considered of poor prognosis in AML (11, 25) . However, in our report no differences occurred in prognostic parameters between the patients with or without 3q chromosome aberrations in the third study group. Although rearrangements of chromosome 3q in AML are strongly associated with normal or elevated PLT counts, other random chromosome alterations or normal karyotypes have also been reported in such cases (1, 3) .
C-mpl proto-oncogene encodes a member of the cytokine receptor superfamily. We have studied the expression of c-mpl in a series of 105 patients with hematologic malignancies using Northern blot analysis. While the levels of c-mpl transcripts in lymphoid malignancies and in chronic myeloproliferative disorders are not significantly different from those found in normal bone marrow cells, the c-mpl expression is increased in patients with AML and in MDS. There is no significant correlation between c-mpl expression and the FAB classification of AML. Results from several studies suggest that c-mpl protein overexpression in AML plays a role in the aggressiveness of disease and is of prognostic relevance. Patients with high c-mpl expression appeared to belong to a subgroup of AML with a low rate of complete remission and a poor prognosis, including secondary leukemia and AML with unfavourable cytogenetic abnormalities (10, 16, 17, 26) . However, no overexpression of c-mpl protein or mRNA was found in typical 3q syndrome AML cases (27) . Moreover, in our study the c-mpl levels were directly correlated with the prognosis in the three AML patient groups and the highest c-mpl expression was observed in AML patients with normal or elevated PLT counts (Group 3, Table III ). Chelvatheebam et al summarized the incidence and prognostic significance of c-mpl expression in AML (28) , and more recently Corrazza et al suggested that in patients with AML, TPO levels could be secondary to TPO clearing by functional c-mpl receptor myeloid blast cells and that TPO may serve as an in vivo myeloid leukemic growth factor in a significant number of patients (29) .
Conclusively, AML patients with normal or elevated PLT counts may constitute a distinct patient group with particular characteristics such as high levels of endogenous TPO production, high expression of CD34 + leukemic blast cells, higher expression of c-mpl and consequently low response to chemotherapy and very poor prognosis. Our data suggest a need for further studies in an attempt to develop risk-adapted AML targeted therapies and treatment strategies.
